Cargando…

The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies

Muscular dystrophies are inherited neuromuscular diseases, resulting in progressive disability and often affecting life expectancy. The most severe, common types are Duchenne muscular dystrophy (DMD) and Limb-girdle sarcoglycanopathy, which cause advancing muscle weakness and wasting. These diseases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zabłocki, Krzysztof, Górecki, Dariusz C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253798/ https://www.ncbi.nlm.nih.gov/pubmed/37298386 http://dx.doi.org/10.3390/ijms24119434

Ejemplares similares

Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism
por: Al-Khalidi, Rasha, et al.
Publicado: (2018)

P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment
por: Young, Christopher N J, et al.
Publicado: (2012)

P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy
por: Sinadinos, Anthony, et al.
Publicado: (2015)

P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles
por: Rumney, Robin M. H., et al.
Publicado: (2022)

P2RX7 Purinoceptor as a Therapeutic Target—The Second Coming?
por: Young, Chris N. J., et al.
Publicado: (2018)

Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences
por: Zabłocka, Barbara, et al.
Publicado: (2021)

Primary mouse myoblast metabotropic purinoceptor profiles and calcium signalling differ with their muscle origin and are altered in mdx dystrophinopathy
por: Róg, Justyna, et al.
Publicado: (2023)

Specific Dystrophins Selectively Associate with Inhibitory and Excitatory Synapses of the Mouse Cerebellum and their Loss Alters Expression of P2X7 Purinoceptors and Pro-Inflammatory Mediators
por: Jackson, Torquil, et al.
Publicado: (2021)

Aberrant Location of Inhibitory Synaptic Marker Proteins in the Hippocampus of Dystrophin-Deficient Mice: Implications for Cognitive Impairment in Duchenne Muscular Dystrophy
por: Krasowska, Elżbieta, et al.
Publicado: (2014)

The P2 purinoceptors in prostate cancer
por: Wang, Zilin, et al.
Publicado: (2022)

Single Channel Properties of P2X(2) Purinoceptors
por: Ding, Shinghua, et al.
Publicado: (1999)

Role of P2X Purinoceptor 7 in Neurogenic Pulmonary Edema after Subarachnoid Hemorrhage in Rats
por: Chen, Sheng, et al.
Publicado: (2014)

P2X7 purinoceptors contribute to the death of Schwann cells transplanted into the spinal cord
por: Luo, J, et al.
Publicado: (2013)

Impact of P2X(7) Purinoceptors on Goblet Cell Function: Implications for Dry Eye
por: Puro, Donald G.
Publicado: (2021)

A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies
por: Pradhan, Bhola Shankar, et al.
Publicado: (2020)

Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors
por: Kurashima, Yosuke, et al.
Publicado: (2012)

microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus
por: Jimenez-Mateos, Eva M., et al.
Publicado: (2015)

The Immune System in Duchenne Muscular Dystrophy Pathogenesis
por: Tripodi, Luana, et al.
Publicado: (2021)

Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia
por: Ochi-ishi, Ryutaro, et al.
Publicado: (2014)

Modulation of P2X Purinoceptor 3 (P2X3) in Pentylenetetrazole-Induced Kindling Epilepsy in Rats
por: Xia, Jie, et al.
Publicado: (2018)

Purinoceptor: a novel target for hypertension
por: Li, Xuan, et al.
Publicado: (2022)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Role for ovarian hormones in purinoceptor-dependent natriuresis
por: Gohar, Eman Y., et al.
Publicado: (2020)

Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases
por: Anwar, Shehata, et al.
Publicado: (2020)

Blocking P2X purinoceptor 4 signalling alleviates cigarette smoke induced pulmonary inflammation
por: Schneider, Sven, et al.
Publicado: (2022)

Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors.
por: Dixon, C. J., et al.
Publicado: (1997)

Estrogen-dependent regulation of transient receptor potential vanilloid 1 (TRPV1) and P2X purinoceptor 3 (P2X3): Implication in burning mouth syndrome
por: Seol, Seon-Hong, et al.
Publicado: (2022)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies
por: Rawls, Alan, et al.
Publicado: (2023)

P2 Receptor Signaling in Motor Units in Muscular Dystrophy
por: Khairullin, Adel E., et al.
Publicado: (2023)

Correction to: Purinoceptor: a novel target for hypertension
por: Li, Xuan, et al.
Publicado: (2023)

Cell culture: complications due to mechanical release of ATP and activation of purinoceptors
por: Burnstock, Geoffrey, et al.
Publicado: (2017)

Progressive Skeletal Muscle Atrophy in Muscular Dystrophies: A Role for Toll-Like Receptor-Signaling in Disease Pathogenesis
por: De Paepe, Boel
Publicado: (2020)

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy
por: Kourakis, Stephanie, et al.
Publicado: (2020)

CRISPR technologies for the treatment of Duchenne muscular dystrophy
por: Choi, Eunyoung, et al.
Publicado: (2021)

P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy
por: Raffaghello, Lizzia, et al.
Publicado: (2022)

Redox Homeostasis in Muscular Dystrophies
por: Mosca, Nicola, et al.
Publicado: (2021)

Current and emerging treatment strategies for Duchenne muscular dystrophy
por: Mah, Jean K
Publicado: (2016)

Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1qijeijokpmui18e7sl7aph9t7